Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

Rituximab did not show superiority over conventional therapy in inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Both treatment groups had similar remission ...

The investigators assessed temporal changes in patterns of induction therapy, and evaluated short-term renal and survival outcomes, as well as safety outcomes, prior to and following the introduction ...

Two patients with Waldenstrom’s NHL achieved complete remission with CAR NK cell therapy and rituximab, maintaining remission for 7 and 15 months without further treatment. The therapy is chemotherapy ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...

In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus ...